Scholarlink

<p>This study aimed to investigate the clinical and prognostic significance of activating transcription factor 6 (ATF6) and phosphorylated S6 kinase (pS6K) expression in newly diagnosed diffuse large B-cell lymphoma (DLBCL). We conducted a retrospective analysis of 107 DLBCL patients treated with the R-CHOP regimen at the Department of Hematology, Fourth Hospital of Hebei Medical University, between January 2019 and December 2022. Immunohistochemical staining was performed to evaluate ATF6 and pS6K expression levels in tumor tissues, followed by correlation analyses with clinical features and survival outcomes. Elevated ATF6 and pS6K expression levels were significantly correlated with advanced Ann Arbor stage (III-IV), presence of B symptoms, high International Prognostic Index (IPI) scores (≥ 2), extranodal involvement (&gt; 1 site), peripheral blood lymphopenia (&lt; 1.1 × 10<sup>9</sup>/L), and increased BCL-6 positivity. Survival curve analysis revealed that the overall survival (OS) and progression-free survival (PFS) rates in the high ATF6 (OS, 56.20% vs. 84.40%, <i>P</i> &lt; 0.001; PFS, 41.10% vs. 77.00%, <i>P</i> &lt; 0.001) and pS6K (OS, 52.30% vs. 79.60%, <i>P</i> &lt; 0.001; PFS, 51.80% vs. 64.00%, <i>P</i> = 0.003) expression groups were significantly lower than those in the low expression groups. Multivariate analysis additionally confirmed that B symptoms (HR = 2.819, 95% CI: 1.131–7.027, <i>P</i> = 0.026), IPI scores of 2–3 (HR = 4.906, 95% CI: 1.501–16.042, <i>P</i> = 0.009), and high ATF6 expression (HR = 5.699, 95% CI: 1.223–26.552, <i>P</i> = 0.027) were risk factors for overall survival (OS), whereas the non-germinal center B cell (non-GCB) subtype (HR = 3.245, 95% CI: 1.080–9.748, <i>P</i> = 0.036), IPI scores of 2–3 (HR = 2.776, 95% CI: 1.156–6.662, <i>P</i> = 0.022), and high ATF6 expression (HR = 4.085, 95% CI: 1.418–11.768, <i>P</i> = 0.009) were identified as risk factors for progression-free survival (PFS). ATF6 and pS6K overexpression were strongly associated with aggressive clinicopathological features and closely associated with poor OS and PFS. These findings suggest that ATF6 and pS6K may serve as prognostic biomarkers, highlighting a potential avenue for risk stratification in newly diagnosed DLBCL patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ATF6 and pS6K as prognostic biomarkers in newly diagnosed diffuse large B-cell lymphoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月10日

查看全文
  • Shuang Su,
  • Lili Wu,
  • Chen Huang,
  • Lianjing Wang,
  • Weijing Li,
  • Wei Liu,
  • Lihong Liu

摘要

This study aimed to investigate the clinical and prognostic significance of activating transcription factor 6 (ATF6) and phosphorylated S6 kinase (pS6K) expression in newly diagnosed diffuse large B-cell lymphoma (DLBCL). We conducted a retrospective analysis of 107 DLBCL patients treated with the R-CHOP regimen at the Department of Hematology, Fourth Hospital of Hebei Medical University, between January 2019 and December 2022. Immunohistochemical staining was performed to evaluate ATF6 and pS6K expression levels in tumor tissues, followed by correlation analyses with clinical features and survival outcomes. Elevated ATF6 and pS6K expression levels were significantly correlated with advanced Ann Arbor stage (III-IV), presence of B symptoms, high International Prognostic Index (IPI) scores (≥ 2), extranodal involvement (> 1 site), peripheral blood lymphopenia (< 1.1 × 109/L), and increased BCL-6 positivity. Survival curve analysis revealed that the overall survival (OS) and progression-free survival (PFS) rates in the high ATF6 (OS, 56.20% vs. 84.40%, P < 0.001; PFS, 41.10% vs. 77.00%, P < 0.001) and pS6K (OS, 52.30% vs. 79.60%, P < 0.001; PFS, 51.80% vs. 64.00%, P = 0.003) expression groups were significantly lower than those in the low expression groups. Multivariate analysis additionally confirmed that B symptoms (HR = 2.819, 95% CI: 1.131–7.027, P = 0.026), IPI scores of 2–3 (HR = 4.906, 95% CI: 1.501–16.042, P = 0.009), and high ATF6 expression (HR = 5.699, 95% CI: 1.223–26.552, P = 0.027) were risk factors for overall survival (OS), whereas the non-germinal center B cell (non-GCB) subtype (HR = 3.245, 95% CI: 1.080–9.748, P = 0.036), IPI scores of 2–3 (HR = 2.776, 95% CI: 1.156–6.662, P = 0.022), and high ATF6 expression (HR = 4.085, 95% CI: 1.418–11.768, P = 0.009) were identified as risk factors for progression-free survival (PFS). ATF6 and pS6K overexpression were strongly associated with aggressive clinicopathological features and closely associated with poor OS and PFS. These findings suggest that ATF6 and pS6K may serve as prognostic biomarkers, highlighting a potential avenue for risk stratification in newly diagnosed DLBCL patients.